Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

P. F. Wright, Ruth A Karron, R. B. Belshe, J. Thompson, Jr Crowe J.E., T. G. Boyce, L. L. Halburnt, G. W. Reed, S. S. Whitehead, E. L. Anderson, A. E. Wittek, R. Casey, M. Eichelberger, Bhagvanji Thumar, V. B. Randolph, S. A. Udem, R. M. Chanock, B. R. Murphy

Research output: Contribution to journalArticle

Abstract

A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

Original languageEnglish (US)
Pages (from-to)1331-1342
Number of pages12
JournalJournal of Infectious Diseases
Volume182
Issue number5
DOIs
StatePublished - 2000

Fingerprint

Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Viruses
Vaccines
Respiratory System
Virus Shedding
Attenuated Vaccines
Nose
GTP-Binding Proteins
Immunoglobulin A
Antibody Formation
Fever
Viruses
Mutation
Serum

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. / Wright, P. F.; Karron, Ruth A; Belshe, R. B.; Thompson, J.; Crowe J.E., Jr; Boyce, T. G.; Halburnt, L. L.; Reed, G. W.; Whitehead, S. S.; Anderson, E. L.; Wittek, A. E.; Casey, R.; Eichelberger, M.; Thumar, Bhagvanji; Randolph, V. B.; Udem, S. A.; Chanock, R. M.; Murphy, B. R.

In: Journal of Infectious Diseases, Vol. 182, No. 5, 2000, p. 1331-1342.

Research output: Contribution to journalArticle

Wright, PF, Karron, RA, Belshe, RB, Thompson, J, Crowe J.E., J, Boyce, TG, Halburnt, LL, Reed, GW, Whitehead, SS, Anderson, EL, Wittek, AE, Casey, R, Eichelberger, M, Thumar, B, Randolph, VB, Udem, SA, Chanock, RM & Murphy, BR 2000, 'Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy', Journal of Infectious Diseases, vol. 182, no. 5, pp. 1331-1342. https://doi.org/10.1086/315859
Wright, P. F. ; Karron, Ruth A ; Belshe, R. B. ; Thompson, J. ; Crowe J.E., Jr ; Boyce, T. G. ; Halburnt, L. L. ; Reed, G. W. ; Whitehead, S. S. ; Anderson, E. L. ; Wittek, A. E. ; Casey, R. ; Eichelberger, M. ; Thumar, Bhagvanji ; Randolph, V. B. ; Udem, S. A. ; Chanock, R. M. ; Murphy, B. R. / Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. In: Journal of Infectious Diseases. 2000 ; Vol. 182, No. 5. pp. 1331-1342.
@article{fb3bc01cd0fa4ae0b9f1ab9a54ad80f0,
title = "Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy",
abstract = "A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.",
author = "Wright, {P. F.} and Karron, {Ruth A} and Belshe, {R. B.} and J. Thompson and {Crowe J.E.}, Jr and Boyce, {T. G.} and Halburnt, {L. L.} and Reed, {G. W.} and Whitehead, {S. S.} and Anderson, {E. L.} and Wittek, {A. E.} and R. Casey and M. Eichelberger and Bhagvanji Thumar and Randolph, {V. B.} and Udem, {S. A.} and Chanock, {R. M.} and Murphy, {B. R.}",
year = "2000",
doi = "10.1086/315859",
language = "English (US)",
volume = "182",
pages = "1331--1342",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

AU - Wright, P. F.

AU - Karron, Ruth A

AU - Belshe, R. B.

AU - Thompson, J.

AU - Crowe J.E., Jr

AU - Boyce, T. G.

AU - Halburnt, L. L.

AU - Reed, G. W.

AU - Whitehead, S. S.

AU - Anderson, E. L.

AU - Wittek, A. E.

AU - Casey, R.

AU - Eichelberger, M.

AU - Thumar, Bhagvanji

AU - Randolph, V. B.

AU - Udem, S. A.

AU - Chanock, R. M.

AU - Murphy, B. R.

PY - 2000

Y1 - 2000

N2 - A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

AB - A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants - a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.

UR - http://www.scopus.com/inward/record.url?scp=0033791293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033791293&partnerID=8YFLogxK

U2 - 10.1086/315859

DO - 10.1086/315859

M3 - Article

C2 - 11010838

AN - SCOPUS:0033791293

VL - 182

SP - 1331

EP - 1342

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -